Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Mental Health Market

ID: MRFR/LS/10832-HCR
132 Pages
Vikita Thakur
Last Updated: April 06, 2026

Mental Health Market Research Report: Size, Share, Trend Analysis By Disorder (Schizophrenia, Alcohol Use Disorders, Bipolar Disorder, Depression, Anxiety, Post-traumatic Stress Disorder, Substance Abuse Disorders, Eating Disorders, Other), By Services (Emergency Mental Health Services, Outpatient Counselling, Home-based Treatment Services, Inpatient Hospital Treatment Services, Other), By Age Group (Pediatric, Adult, Geriatric) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World), - Competitor Industry Analysis and Trends Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Mental Health Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Service Type (USD Billion)
  49.     4.1.1 Therapy
  50.     4.1.2 Counseling
  51.     4.1.3 Medication
  52.     4.1.4 Support Groups
  53.   4.2 Healthcare, BY Patient Type (USD Billion)
  54.     4.2.1 Children
  55.     4.2.2 Adolescents
  56.     4.2.3 Adults
  57.     4.2.4 Elderly
  58.   4.3 Healthcare, BY Disorder Type (USD Billion)
  59.     4.3.1 Depression
  60.     4.3.2 Anxiety Disorders
  61.     4.3.3 Bipolar Disorder
  62.     4.3.4 Schizophrenia
  63.   4.4 Healthcare, BY Treatment Setting (USD Billion)
  64.     4.4.1 Inpatient
  65.     4.4.2 Outpatient
  66.     4.4.3 Residential
  67.     4.4.4 Online
  68.   4.5 Healthcare, BY Region (USD Billion)
  69.     4.5.1 North America
  70.       4.5.1.1 US
  71.       4.5.1.2 Canada
  72.     4.5.2 Europe
  73.       4.5.2.1 Germany
  74.       4.5.2.2 UK
  75.       4.5.2.3 France
  76.       4.5.2.4 Russia
  77.       4.5.2.5 Italy
  78.       4.5.2.6 Spain
  79.       4.5.2.7 Rest of Europe
  80.     4.5.3 APAC
  81.       4.5.3.1 China
  82.       4.5.3.2 India
  83.       4.5.3.3 Japan
  84.       4.5.3.4 South Korea
  85.       4.5.3.5 Malaysia
  86.       4.5.3.6 Thailand
  87.       4.5.3.7 Indonesia
  88.       4.5.3.8 Rest of APAC
  89.     4.5.4 South America
  90.       4.5.4.1 Brazil
  91.       4.5.4.2 Mexico
  92.       4.5.4.3 Argentina
  93.       4.5.4.4 Rest of South America
  94.     4.5.5 MEA
  95.       4.5.5.1 GCC Countries
  96.       4.5.5.2 South Africa
  97.       4.5.5.3 Rest of MEA
  98. 5 SECTION V: COMPETITIVE ANALYSIS
  99.   5.1 Competitive Landscape
  100.     5.1.1 Overview
  101.     5.1.2 Competitive Analysis
  102.     5.1.3 Market share Analysis
  103.     5.1.4 Major Growth Strategy in the Healthcare
  104.     5.1.5 Competitive Benchmarking
  105.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  106.     5.1.7 Key developments and growth strategies
  107.       5.1.7.1 New Product Launch/Service Deployment
  108.       5.1.7.2 Merger & Acquisitions
  109.       5.1.7.3 Joint Ventures
  110.     5.1.8 Major Players Financial Matrix
  111.       5.1.8.1 Sales and Operating Income
  112.       5.1.8.2 Major Players R&D Expenditure. 2023
  113.   5.2 Company Profiles
  114.     5.2.1 UnitedHealth Group (US)
  115.       5.2.1.1 Financial Overview
  116.       5.2.1.2 Products Offered
  117.       5.2.1.3 Key Developments
  118.       5.2.1.4 SWOT Analysis
  119.       5.2.1.5 Key Strategies
  120.     5.2.2 Anthem (US)
  121.       5.2.2.1 Financial Overview
  122.       5.2.2.2 Products Offered
  123.       5.2.2.3 Key Developments
  124.       5.2.2.4 SWOT Analysis
  125.       5.2.2.5 Key Strategies
  126.     5.2.3 Cigna (US)
  127.       5.2.3.1 Financial Overview
  128.       5.2.3.2 Products Offered
  129.       5.2.3.3 Key Developments
  130.       5.2.3.4 SWOT Analysis
  131.       5.2.3.5 Key Strategies
  132.     5.2.4 Kaiser Permanente (US)
  133.       5.2.4.1 Financial Overview
  134.       5.2.4.2 Products Offered
  135.       5.2.4.3 Key Developments
  136.       5.2.4.4 SWOT Analysis
  137.       5.2.4.5 Key Strategies
  138.     5.2.5 Magellan Health (US)
  139.       5.2.5.1 Financial Overview
  140.       5.2.5.2 Products Offered
  141.       5.2.5.3 Key Developments
  142.       5.2.5.4 SWOT Analysis
  143.       5.2.5.5 Key Strategies
  144.     5.2.6 Teladoc Health (US)
  145.       5.2.6.1 Financial Overview
  146.       5.2.6.2 Products Offered
  147.       5.2.6.3 Key Developments
  148.       5.2.6.4 SWOT Analysis
  149.       5.2.6.5 Key Strategies
  150.     5.2.7 Mental Health America (US)
  151.       5.2.7.1 Financial Overview
  152.       5.2.7.2 Products Offered
  153.       5.2.7.3 Key Developments
  154.       5.2.7.4 SWOT Analysis
  155.       5.2.7.5 Key Strategies
  156.     5.2.8 LivaNova (GB)
  157.       5.2.8.1 Financial Overview
  158.       5.2.8.2 Products Offered
  159.       5.2.8.3 Key Developments
  160.       5.2.8.4 SWOT Analysis
  161.       5.2.8.5 Key Strategies
  162.     5.2.9 HCA Healthcare (US)
  163.       5.2.9.1 Financial Overview
  164.       5.2.9.2 Products Offered
  165.       5.2.9.3 Key Developments
  166.       5.2.9.4 SWOT Analysis
  167.       5.2.9.5 Key Strategies
  168.     5.2.10 Acadia Healthcare (US)
  169.       5.2.10.1 Financial Overview
  170.       5.2.10.2 Products Offered
  171.       5.2.10.3 Key Developments
  172.       5.2.10.4 SWOT Analysis
  173.       5.2.10.5 Key Strategies
  174.   5.3 Appendix
  175.     5.3.1 References
  176.     5.3.2 Related Reports
  177. 6 LIST OF FIGURES
  178.   6.1 MARKET SYNOPSIS
  179.   6.2 NORTH AMERICA MARKET ANALYSIS
  180.   6.3 US MARKET ANALYSIS BY SERVICE TYPE
  181.   6.4 US MARKET ANALYSIS BY PATIENT TYPE
  182.   6.5 US MARKET ANALYSIS BY DISORDER TYPE
  183.   6.6 US MARKET ANALYSIS BY TREATMENT SETTING
  184.   6.7 CANADA MARKET ANALYSIS BY SERVICE TYPE
  185.   6.8 CANADA MARKET ANALYSIS BY PATIENT TYPE
  186.   6.9 CANADA MARKET ANALYSIS BY DISORDER TYPE
  187.   6.10 CANADA MARKET ANALYSIS BY TREATMENT SETTING
  188.   6.11 EUROPE MARKET ANALYSIS
  189.   6.12 GERMANY MARKET ANALYSIS BY SERVICE TYPE
  190.   6.13 GERMANY MARKET ANALYSIS BY PATIENT TYPE
  191.   6.14 GERMANY MARKET ANALYSIS BY DISORDER TYPE
  192.   6.15 GERMANY MARKET ANALYSIS BY TREATMENT SETTING
  193.   6.16 UK MARKET ANALYSIS BY SERVICE TYPE
  194.   6.17 UK MARKET ANALYSIS BY PATIENT TYPE
  195.   6.18 UK MARKET ANALYSIS BY DISORDER TYPE
  196.   6.19 UK MARKET ANALYSIS BY TREATMENT SETTING
  197.   6.20 FRANCE MARKET ANALYSIS BY SERVICE TYPE
  198.   6.21 FRANCE MARKET ANALYSIS BY PATIENT TYPE
  199.   6.22 FRANCE MARKET ANALYSIS BY DISORDER TYPE
  200.   6.23 FRANCE MARKET ANALYSIS BY TREATMENT SETTING
  201.   6.24 RUSSIA MARKET ANALYSIS BY SERVICE TYPE
  202.   6.25 RUSSIA MARKET ANALYSIS BY PATIENT TYPE
  203.   6.26 RUSSIA MARKET ANALYSIS BY DISORDER TYPE
  204.   6.27 RUSSIA MARKET ANALYSIS BY TREATMENT SETTING
  205.   6.28 ITALY MARKET ANALYSIS BY SERVICE TYPE
  206.   6.29 ITALY MARKET ANALYSIS BY PATIENT TYPE
  207.   6.30 ITALY MARKET ANALYSIS BY DISORDER TYPE
  208.   6.31 ITALY MARKET ANALYSIS BY TREATMENT SETTING
  209.   6.32 SPAIN MARKET ANALYSIS BY SERVICE TYPE
  210.   6.33 SPAIN MARKET ANALYSIS BY PATIENT TYPE
  211.   6.34 SPAIN MARKET ANALYSIS BY DISORDER TYPE
  212.   6.35 SPAIN MARKET ANALYSIS BY TREATMENT SETTING
  213.   6.36 REST OF EUROPE MARKET ANALYSIS BY SERVICE TYPE
  214.   6.37 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE
  215.   6.38 REST OF EUROPE MARKET ANALYSIS BY DISORDER TYPE
  216.   6.39 REST OF EUROPE MARKET ANALYSIS BY TREATMENT SETTING
  217.   6.40 APAC MARKET ANALYSIS
  218.   6.41 CHINA MARKET ANALYSIS BY SERVICE TYPE
  219.   6.42 CHINA MARKET ANALYSIS BY PATIENT TYPE
  220.   6.43 CHINA MARKET ANALYSIS BY DISORDER TYPE
  221.   6.44 CHINA MARKET ANALYSIS BY TREATMENT SETTING
  222.   6.45 INDIA MARKET ANALYSIS BY SERVICE TYPE
  223.   6.46 INDIA MARKET ANALYSIS BY PATIENT TYPE
  224.   6.47 INDIA MARKET ANALYSIS BY DISORDER TYPE
  225.   6.48 INDIA MARKET ANALYSIS BY TREATMENT SETTING
  226.   6.49 JAPAN MARKET ANALYSIS BY SERVICE TYPE
  227.   6.50 JAPAN MARKET ANALYSIS BY PATIENT TYPE
  228.   6.51 JAPAN MARKET ANALYSIS BY DISORDER TYPE
  229.   6.52 JAPAN MARKET ANALYSIS BY TREATMENT SETTING
  230.   6.53 SOUTH KOREA MARKET ANALYSIS BY SERVICE TYPE
  231.   6.54 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE
  232.   6.55 SOUTH KOREA MARKET ANALYSIS BY DISORDER TYPE
  233.   6.56 SOUTH KOREA MARKET ANALYSIS BY TREATMENT SETTING
  234.   6.57 MALAYSIA MARKET ANALYSIS BY SERVICE TYPE
  235.   6.58 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE
  236.   6.59 MALAYSIA MARKET ANALYSIS BY DISORDER TYPE
  237.   6.60 MALAYSIA MARKET ANALYSIS BY TREATMENT SETTING
  238.   6.61 THAILAND MARKET ANALYSIS BY SERVICE TYPE
  239.   6.62 THAILAND MARKET ANALYSIS BY PATIENT TYPE
  240.   6.63 THAILAND MARKET ANALYSIS BY DISORDER TYPE
  241.   6.64 THAILAND MARKET ANALYSIS BY TREATMENT SETTING
  242.   6.65 INDONESIA MARKET ANALYSIS BY SERVICE TYPE
  243.   6.66 INDONESIA MARKET ANALYSIS BY PATIENT TYPE
  244.   6.67 INDONESIA MARKET ANALYSIS BY DISORDER TYPE
  245.   6.68 INDONESIA MARKET ANALYSIS BY TREATMENT SETTING
  246.   6.69 REST OF APAC MARKET ANALYSIS BY SERVICE TYPE
  247.   6.70 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE
  248.   6.71 REST OF APAC MARKET ANALYSIS BY DISORDER TYPE
  249.   6.72 REST OF APAC MARKET ANALYSIS BY TREATMENT SETTING
  250.   6.73 SOUTH AMERICA MARKET ANALYSIS
  251.   6.74 BRAZIL MARKET ANALYSIS BY SERVICE TYPE
  252.   6.75 BRAZIL MARKET ANALYSIS BY PATIENT TYPE
  253.   6.76 BRAZIL MARKET ANALYSIS BY DISORDER TYPE
  254.   6.77 BRAZIL MARKET ANALYSIS BY TREATMENT SETTING
  255.   6.78 MEXICO MARKET ANALYSIS BY SERVICE TYPE
  256.   6.79 MEXICO MARKET ANALYSIS BY PATIENT TYPE
  257.   6.80 MEXICO MARKET ANALYSIS BY DISORDER TYPE
  258.   6.81 MEXICO MARKET ANALYSIS BY TREATMENT SETTING
  259.   6.82 ARGENTINA MARKET ANALYSIS BY SERVICE TYPE
  260.   6.83 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE
  261.   6.84 ARGENTINA MARKET ANALYSIS BY DISORDER TYPE
  262.   6.85 ARGENTINA MARKET ANALYSIS BY TREATMENT SETTING
  263.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY SERVICE TYPE
  264.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE
  265.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISORDER TYPE
  266.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT SETTING
  267.   6.90 MEA MARKET ANALYSIS
  268.   6.91 GCC COUNTRIES MARKET ANALYSIS BY SERVICE TYPE
  269.   6.92 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE
  270.   6.93 GCC COUNTRIES MARKET ANALYSIS BY DISORDER TYPE
  271.   6.94 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT SETTING
  272.   6.95 SOUTH AFRICA MARKET ANALYSIS BY SERVICE TYPE
  273.   6.96 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE
  274.   6.97 SOUTH AFRICA MARKET ANALYSIS BY DISORDER TYPE
  275.   6.98 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT SETTING
  276.   6.99 REST OF MEA MARKET ANALYSIS BY SERVICE TYPE
  277.   6.100 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE
  278.   6.101 REST OF MEA MARKET ANALYSIS BY DISORDER TYPE
  279.   6.102 REST OF MEA MARKET ANALYSIS BY TREATMENT SETTING
  280.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  281.   6.104 RESEARCH PROCESS OF MRFR
  282.   6.105 DRO ANALYSIS OF HEALTHCARE
  283.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  284.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  285.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  286.   6.109 HEALTHCARE, BY SERVICE TYPE, 2024 (% SHARE)
  287.   6.110 HEALTHCARE, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
  288.   6.111 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE)
  289.   6.112 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion)
  290.   6.113 HEALTHCARE, BY DISORDER TYPE, 2024 (% SHARE)
  291.   6.114 HEALTHCARE, BY DISORDER TYPE, 2024 TO 2035 (USD Billion)
  292.   6.115 HEALTHCARE, BY TREATMENT SETTING, 2024 (% SHARE)
  293.   6.116 HEALTHCARE, BY TREATMENT SETTING, 2024 TO 2035 (USD Billion)
  294.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  295. 7 LIST OF TABLES
  296.   7.1 LIST OF ASSUMPTIONS
  297.     7.1.1
  298.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  299.     7.2.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  300.     7.2.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  301.     7.2.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  302.     7.2.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  303.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  304.     7.3.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  305.     7.3.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  306.     7.3.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  307.     7.3.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  308.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  309.     7.4.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  310.     7.4.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  311.     7.4.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  312.     7.4.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  313.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  314.     7.5.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  315.     7.5.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  316.     7.5.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  317.     7.5.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  318.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  319.     7.6.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  320.     7.6.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  321.     7.6.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  322.     7.6.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  323.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  324.     7.7.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  325.     7.7.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  326.     7.7.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  327.     7.7.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  328.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  329.     7.8.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  330.     7.8.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  331.     7.8.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  332.     7.8.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  333.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  334.     7.9.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  335.     7.9.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  336.     7.9.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  337.     7.9.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  338.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  339.     7.10.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  340.     7.10.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  341.     7.10.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  342.     7.10.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  343.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  344.     7.11.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  345.     7.11.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  346.     7.11.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  347.     7.11.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  348.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  349.     7.12.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  350.     7.12.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  351.     7.12.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  352.     7.12.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  353.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  354.     7.13.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  355.     7.13.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  356.     7.13.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  357.     7.13.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  358.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  359.     7.14.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  360.     7.14.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  361.     7.14.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  362.     7.14.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  363.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  364.     7.15.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  365.     7.15.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  366.     7.15.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  367.     7.15.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  368.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  369.     7.16.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  370.     7.16.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  371.     7.16.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  372.     7.16.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  373.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  374.     7.17.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  375.     7.17.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  376.     7.17.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  377.     7.17.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  378.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  379.     7.18.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  380.     7.18.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  381.     7.18.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  382.     7.18.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  383.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  384.     7.19.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  385.     7.19.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  386.     7.19.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  387.     7.19.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  388.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  389.     7.20.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  390.     7.20.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  391.     7.20.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  392.     7.20.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  393.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  394.     7.21.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  395.     7.21.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  396.     7.21.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  397.     7.21.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  398.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  399.     7.22.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  400.     7.22.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  401.     7.22.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  402.     7.22.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  403.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  404.     7.23.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  405.     7.23.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  406.     7.23.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  407.     7.23.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  408.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  409.     7.24.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  410.     7.24.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  411.     7.24.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  412.     7.24.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  413.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  414.     7.25.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  415.     7.25.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  416.     7.25.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  417.     7.25.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  418.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  419.     7.26.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  420.     7.26.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  421.     7.26.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  422.     7.26.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  423.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  424.     7.27.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  425.     7.27.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  426.     7.27.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  427.     7.27.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  428.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  429.     7.28.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  430.     7.28.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  431.     7.28.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  432.     7.28.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  433.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  434.     7.29.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  435.     7.29.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  436.     7.29.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  437.     7.29.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  438.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  439.     7.30.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
  440.     7.30.2 BY PATIENT TYPE, 2025-2035 (USD Billion)
  441.     7.30.3 BY DISORDER TYPE, 2025-2035 (USD Billion)
  442.     7.30.4 BY TREATMENT SETTING, 2025-2035 (USD Billion)
  443.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  444.     7.31.1
  445.   7.32 ACQUISITION/PARTNERSHIP
  446.     7.32.1

Healthcare Market Segmentation

Healthcare By Service Type (USD Billion, 2025-2035)

  • Therapy
  • Counseling
  • Medication
  • Support Groups

Healthcare By Patient Type (USD Billion, 2025-2035)

  • Children
  • Adolescents
  • Adults
  • Elderly

Healthcare By Disorder Type (USD Billion, 2025-2035)

  • Depression
  • Anxiety Disorders
  • Bipolar Disorder
  • Schizophrenia

Healthcare By Treatment Setting (USD Billion, 2025-2035)

  • Inpatient
  • Outpatient
  • Residential
  • Online

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions